Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8
|
作者：
Wang, Yonghua [1 ]
Yang, Meng [1 ]
Yu, Qinchao [1 ]
Yu, Lun [1 ]
Shao, Shixiu [1 ]
Wang, Xinsheng [1 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;
D O I：
10.1586/14737140.2015.961430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.
引用
收藏
页码：85 / 93
页数：9
相关论文
共 50 条
  • [1] Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder
    Kresowik, Timothy P.
    Griffith, Thomas S.
    IMMUNOTHERAPY, 2009, 1 (02) : 281 - 288
  • [2] Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy
    Zheng, Yuan-qiang
    Naguib, Youssef W.
    Dong, Yixuan
    Shi, Yan-chun
    Bou, Shorgan
    Cui, Zhengrong
    EXPERT REVIEW OF VACCINES, 2015, 14 (09) : 1255 - 1275
  • [3] Bacillus Calmette-Guerin immunotherapy for genitourinary cancer
    Gandhi, Nilay M.
    Morales, Alvaro
    Lamm, Donald L.
    BJU INTERNATIONAL, 2013, 112 (03) : 288 - 297
  • [4] Bacillus Calmette-Guerin and bladder cancer
    Razack, Azad H. A.
    ASIAN JOURNAL OF SURGERY, 2007, 30 (04) : 302 - 309
  • [5] Pleural Effusion Caused by Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer
    Rachakonda, Tara
    Kendall, Brian
    Spivak, Adam M.
    Boltax, Jonathan
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (03):
  • [6] Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages
    Khanna, Abhinav
    Yerram, Nitin
    Zhu, Hui
    Kim, Simon
    Abouassaly, Robert
    UROLOGY, 2019, 124 : 120 - 125
  • [7] Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy
    Shintani, Yasuyo
    Sawada, Yoshihisa
    Inagaki, Takeshi
    Kohjimoto, Yasuo
    Uekado, Yasunari
    Shinka, Toshiaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (02) : 140 - 146
  • [8] Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections
    Larsen, Emilie Stavnsbjerg
    Joensen, Ulla Nordstroem
    Poulsen, Alicia Martin
    Goletti, Delia
    Johansen, Isik Somuncu
    APMIS, 2020, 128 (02) : 92 - 103
  • [9] Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer
    Hugar, Lee A.
    Gilbert, Scott M.
    Sexton, Wade J.
    Kamat, Ashish M.
    Li, Roger
    CURRENT OPINION IN UROLOGY, 2021, 31 (02) : 160 - 169
  • [10] Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer
    Böhle, A
    Brandau, S
    JOURNAL OF UROLOGY, 2003, 170 (03) : 964 - 969
12345